We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Natural History of Coronary Heart Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00005265
First Posted: May 26, 2000
Last Update Posted: May 13, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Heart, Lung, and Blood Institute (NHLBI)
  Purpose
To examine the natural history of mortality due to coronary heart disease in post-myocardial infarction patients from the Beta-Blocker Heart Attack Trial (BHAT) and the Aspirin Myocardial Infarction Study (AMIS).

Condition
Cardiovascular Diseases Coronary Disease Myocardial Infarction Heart Diseases Death, Sudden, Cardiac Heart Failure, Congestive Heart Failure

Study Type: Observational

Resource links provided by NLM:


Further study details as provided by National Heart, Lung, and Blood Institute (NHLBI):

Study Start Date: September 1990
Study Completion Date: May 1992
Detailed Description:

BACKGROUND:

In January 1990, the National Heart, Lung, and Blood Institute issued a Program Announcement establishing a Small Grants Program to provide limited support to extend analyses of research data generated by clinical trials, population research, and demonstration and education studies. This study used data collected in two completed clinical trials, the BHAT and AMIS.

DESIGN NARRATIVE:

Study endpoints included all-cause mortality, cause-specific mortality such as sudden death, recurrent and non-fatal myocardial infarction, and incident congestive heart failure. Univariate and multivariate analyses of baseline data variables from BHAT were conducted to determine which were predictive of study endpoints. Baseline variables included sociodemograhic characteristics, medical history, medication use, physical examination finds, and electrocardiographic characteristics. Baseline characteristics found to be predictive of study endpoints in the BHAT placebo group were examined in the AMIS placebo group. Long- and short-term prognoses for patients suffering a transmural myocardial infarction were compared for those suffering a subendocardial infarction.

The study completion date listed in this record was obtained from the "End Date" entered in the Protocol Registration and Results System (PRS) record.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   up to 100 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria
No eligibility criteria
  Contacts and Locations
No Contacts or Locations Provided
  More Information

ClinicalTrials.gov Identifier: NCT00005265     History of Changes
Other Study ID Numbers: 1149
R03HL045495 ( U.S. NIH Grant/Contract )
First Submitted: May 25, 2000
First Posted: May 26, 2000
Last Update Posted: May 13, 2016
Last Verified: November 2001

Additional relevant MeSH terms:
Heart Failure
Infarction
Cardiovascular Diseases
Heart Diseases
Myocardial Infarction
Coronary Disease
Coronary Artery Disease
Death, Sudden
Death, Sudden, Cardiac
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Vascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Death
Heart Arrest